top of page
Mike Conlon is currently the president of Stillpine Consulting, a quantitative focused firm that works closely with early-stage biotech companies on a variety of new product projects including indication prioritization, corporate strategy, forecasting and market assessments. Mike has 20 years of industry experience with new products/corporate strategy roles of increasing responsibility at Biogen, Shire, Kaleido and Synlogic. He started out his career in the lab as a scientist in the discovery group at Pfizer. Mike also spent several years as a consultant at Trinity Partners and holds a BA in biochemistry from Skidmore College and an MBA from the Tuck School of Business at Dartmouth.
bottom of page